SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-365547
Filing Date
2021-12-23
Accepted
2021-12-23 06:08:32
Documents
17
Period of Report
2021-12-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d270834d8k.htm   iXBRL 8-K 35111
2 EX-1.1 d270834dex11.htm EX-1.1 151139
3 EX-5.1 d270834dex51.htm EX-5.1 8858
4 EX-5.2 d270834dex52.htm EX-5.2 8164
8 GRAPHIC g270834g1222021528442.jpg GRAPHIC 3480
9 GRAPHIC g270834g1223002009527.jpg GRAPHIC 3471
  Complete submission text file 0001193125-21-365547.txt   393759

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA alna-20211223.xsd EX-101.SCH 2905
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE alna-20211223_lab.xml EX-101.LAB 18889
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alna-20211223_pre.xml EX-101.PRE 11869
11 EXTRACTED XBRL INSTANCE DOCUMENT d270834d8k_htm.xml XML 3785
Mailing Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462
Business Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

IRS No.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38268 | Film No.: 211514736
SIC: 2836 Biological Products, (No Diagnostic Substances)